Quantitative MRI in Assessing Disease in Patients With Brain Tumors
NCT ID: NCT02269111
Last Updated: 2018-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
10 participants
INTERVENTIONAL
2015-04-30
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery
NCT02277561
7T MRI Scan for the Early Detection of Melanoma Brain Metastases
NCT04941430
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
NCT01557881
Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging
NCT02311556
18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors
NCT02167204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To correlate pre-treatment measures of biophysical parameters in metastases-obtained using advanced, quantitative MRI techniques in patients receiving standard-of-care (SOC) therapy for 1-4 brain metastases-with treatment-induced changes in lesion size, time-to-progression (TTP), and overall survival (OS).
OUTLINE:
Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, diffusion-weighted (DW)-MRI, chemical exchange saturation transfer (CEST), and combined dynamic contrast enhanced (DCE)-MRI/dynamic susceptibility contrast (DSC)-MRI at baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic (hybrid MRI)
Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
diffusion-weighted magnetic resonance imaging
Undergo DW-MRI
chemical exchange saturation transfer magnetic resonance imaging
Undergo CEST-MRI
dynamic contrast-enhanced magnetic resonance imaging
Undergo DCE-MRI
dynamic susceptibility contrast-enhanced magnetic resonance imaging
Undergo DSC-MRI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
diffusion-weighted magnetic resonance imaging
Undergo DW-MRI
chemical exchange saturation transfer magnetic resonance imaging
Undergo CEST-MRI
dynamic contrast-enhanced magnetic resonance imaging
Undergo DCE-MRI
dynamic susceptibility contrast-enhanced magnetic resonance imaging
Undergo DSC-MRI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have been diagnosed with one of the following:
* Primary brain tumor (glioma, GBM etc); or
* Up to 10 brain metastases
* Patients must have been diagnosed with 1-4 brain metastases
* At least one of the brain metastases must measure 5 mm (or more) in short axis diameter in the axial plane
* Patients must be scheduled to undergo standard brain cancer interventions:
* Chemotherapy or targeted antiangiogenic therapy, in the case of primary brain tumor; or
* Stereotaxic radiotherapy (SRS) or whole brain radiotherapy (WBRT), in the case of brain metastases.
* Patients must be scheduled to receive a 3-Tesla (3T) MRI exam as part of their standard of care (this exam will be modified to also include pulse sequences with are for research only)
Exclusion Criteria
* Patients who are scheduled to receive a 1.5T MRI exam
* Patients incapable of giving informed written consent, due to mental disability, altered mental status, confusion, cognitive impairment, or psychiatric disorders.
* Patients scoring 14.5 or lower on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) questionnaire will not be allowed on the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Albert Attia
Assistant Professor of Radiation Oncology; Radiation Oncologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Albert Attia, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Vanderbilt-Ingram Cancer Center, Find a Clinical Trial
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2014-01907
Identifier Type: REGISTRY
Identifier Source: secondary_id
VICC NEU1424
Identifier Type: OTHER
Identifier Source: secondary_id
VICC NEU1424
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.